CAS: 139262-76-3
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | H2L5186303 REF: IN-DA00A0N1CAS: 139262-76-3 | 97% | To inquire | Fri 15 Nov 24 |
 | H2L5186303 REF: 3D-PFA26276CAS: 139262-76-3 | Min. 95% | To inquire | Fri 27 Dec 24 |
 | H2L5186303 REF: TM-T22835CAS: 139262-76-3 | 97.23% | 35.00 €~917.00 € | Fri 03 Jan 25 |
Ref: IN-DA00A0N1
| 25mg | 171.00 € | ||
| 50mg | 206.00 € | ||
| 100mg | 464.00 € |
Estimated delivery in United States, on Friday 15 Nov 2024
H2L5186303
CAS:139262-76-3
H2L5186303 is a synthetic endocannabinoid that has been shown to have anticancer effects. H2L5186303 binds …
Formula:
C26H20N2O8
Purity:
Min. 95%
Molecular weight:
488.45 g/mol
Ref: 3D-PFA26276
| 25mg | To inquire | ||
| 50mg | To inquire | ||
| 100mg | To inquire |
Estimated delivery in United States, on Friday 27 Dec 2024
H2L5186303
CAS:139262-76-3
H2L5186303 is an LPA2 antagonist and can be used in studies about asthma treatment.
Formula:
C26H20N2O8
Purity:
97.23%
Color and Shape:
Solid
Molecular weight:
488.45
Ref: TM-T22835
| 1mg | 35.00 € | ||
| 5mg | 63.00 € | ||
| 10mg | 102.00 € | ||
| 25mg | 221.00 € | ||
| 50mg | 328.00 € | ||
| 100mg | 460.00 € | ||
| 500mg | 917.00 € | ||
| 1mL*10mM (DMSO) | 76.00 € |
Estimated delivery in United States, on Friday 3 Jan 2025
